良性和恶性胃部疾病中的肿瘤相关胰蛋白酶抑制剂（TATI）

Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.

作者信息

Loizate Toricaguena A, Lamiquiz Vallejo A, Dominguez Merru-Urrutia M J, Legorburu Escudero J F

机构信息

Cruces' Hospital, Baracaldo (Vizcaya), Spain.

出版信息

Scand J Clin Lab Invest Suppl. 1991;207:59-62. doi: 10.3109/00365519109104629.

DOI:10.3109/00365519109104629

PMID:1780694

Abstract

We have evaluated the clinical utility of tumor-associated trypsin inhibitor (TATI) as a marker for gastric cancer. For comparison we also studied CEA, CA19-9, CA-50 and TPA. The study comprised 93 patients with cancer and 45 with gastroduodenal ulcers. In 95% of the patients with benign disease the serum TATI concentrations were below 30 micrograms/l. Using this concentration as cut-off level 46% of the cancer patients had elevated levels. These were most common in advanced disease (68% in stage IVB) and patients with anaplastic tumors. Therefore TATI was a useful complement to CEA, which was most often elevated in patients with differentiated tumors. Addition of TATI to the battery of other markers increased the overall sensitivity for cancer from 69% to 80%.

摘要

我们评估了肿瘤相关胰蛋白酶抑制剂（TATI）作为胃癌标志物的临床效用。为作比较，我们还研究了癌胚抗原（CEA）、糖类抗原19-9（CA19-9）、糖类抗原50（CA-50）和组织多肽抗原（TPA）。该研究纳入了93例癌症患者和45例胃十二指肠溃疡患者。95%的良性疾病患者血清TATI浓度低于30微克/升。以该浓度作为临界值，46%的癌症患者TATI水平升高。这些情况在晚期疾病（IVB期患者中占68%）和间变性肿瘤患者中最为常见。因此，TATI是对CEA的有益补充，CEA在分化型肿瘤患者中最常升高。将TATI添加到其他标志物组合中，使癌症的总体敏感性从69%提高到了80%。